SEARCH

SEARCH BY CITATION

References

  • 1
    Andlin-Sobocki P, Jönsson B, Wittchen H-U, Olesen J. Cost of disorders of the brain in Europe. European Journal of Dementia 2005; 12(Suppl. 1): 127.
  • 2
    Olesen J, Leonardi M. The burden of brain diseases in Europe. European Journal of Neurology 2003; 10: 471477.
  • 3
    Jönsson L, Berr C. Cost of dementia in Europe. European Journal of Neurology 2005; 12(Suppl. 1): 5053.
  • 4
    Waldemar G, Phungh KTT, Burns A, Georges J, Hansen FR, Iliffe S, Marking C, Olde-Rikkert M, Selmes J, Stoppe G, Sartorius N. Access to diagnostic evaluation and treatment for dementia in Europe. International Journal of Geriatric Psychiatry 2006; Oct 17; (Epub ahead of print).
  • 5
    Waldemar G, Dubois B, Emre M, Scheltens P, Tariska P, Rossor M. Diagnosis and management of Alzheimer's disease and related disorders: the role of neurologists in Europe. European Journal of Neurology 2000; 7: 133144.
  • 6
    Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: Early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the quality standards subcommittee of the Amerian Academy of Neurology. Neurology 2001; 56: 11331142.
  • 7
    Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the Amerian Academy of Neurology. Neurology 2001; 56: 11431153.
  • 8
    Doody RC, Stevens JC, Beck RN, et al. Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the Amerian Academy of Neurology. Neurology 2001; 56: 11541166.
  • 9
    Brainin M, Barnes M, Gilhus NE, Selmaj K, Waldemar G. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations. European Journal of Neurology 2004; 11: 577581.
  • 10
    American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. DSM-IV, 4th edn. Washington, DC: American Psychiatric Association, 1993.
  • 11
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinial diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939944.
  • 12
    McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996; 47, 11131124.
  • 13
    Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 15461554.
  • 14
    McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and Pathological Diagnosis of Frontotemporal Dementia: Report of the Work Group on Frontotemporal Dementia and Pick's Disease. Archives of Neurology 2001; 58: 18031809.
  • 15
    Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250260.
  • 16
    Holmes C, Cairns N, Lantos P, et al. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. British Journal of Psychiatry 1999; 174: 4550.
  • 17
    Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychological Medicine 1989; 19: 10151022.
  • 18
    Fuh JL, Teng EL, Lin KN, et al. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) as a screening tool for dementia for a predominantly illiterate Chinese population. Neurology 1995; 45: 9296.
  • 19
    Lam LC, Chiu HF, Li SW, et al. Screening for dementia: a preliminary study on the validity of the Chinese version of the Blessed-Roth Dementia Scale. International Psychogeriatrics 1997; 9: 3946.
  • 20
    Mackinnon A, Mulligan R. Combining cognitive testing and informant report to increase accuracy in screening for dementia. American Journal of Psychiatry 1998; 155: 15291535.
  • 21
    Mackinnon A, Khalilian A, Jorm AF, Korten AE, Christensen H, Mulligan R. Improving screening accuracy for dementia in a community sample by augmenting cognitive testing with informant report. Journal of Clinical Epidemiology 2003; 56: 358366.
  • 22
    Jorm AF. Methods of screening for dementia: a meta-analysis of studies comparing an informant questionnaire with a brief cognitive test. Alzheimer's Disease and Associated Disorders 1997; 11: 158162.
  • 23
    Folstein MF, Folstein SE, McHugh PR. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1995; 12: 189198.
  • 24
    Juva K, Sulkava R, Erkinjutti K, Ylikoski R, Valvanne J, Tilvis R. Usefulness of the clinical Dementia Rating scale in screening for dementia. International Psychogeriatrics 1995; 7: 1724.
  • 25
    Solomon PR, Hirschoff A, Kelly B, et al. A 7-minute neurocognitive screening battery highly sensitive to Alzheimer's disease. Archives of Neurology 1998; 55: 349355.
  • 26
    Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: BellackL, KarusuTB eds. Geriatric Psychiatry: a Handbook for Psychiatrist and Primary Care Physicians. New York: Grune & Straton, 1976: 77121.
  • 27
    Incalzi RA, Capparella O, Gemma A, Marra C, Carbonin P. Effects of aging and of Alzheimer's disease on verbal memory. Journal of Clinical and Experimental Neuropsychology 1995; 17: 580589.
  • 28
    Pillon B, Dubois B, Agid Y. Testing cognition may contribute to the diagnosis of movement disorders. Neurology 1996; 46: 329333.
  • 29
    Buschke H, Kuslansky G, Katz M, et al. Screening for dementia with the Memory impairment Screen. Neurology 1999; 52: 31238.
  • 30
    Dubois B, Touchon J, Portet F, Ousset PJ, Vellas B, Michel B. The ‘5 words’ test: a simple and sensitive test for the diagnosis of Alzheimer's disease. Presse Médicale 2002; 31: 16961699.
  • 31
    Hodges JR, Patterson K, Oxbury S, Funnell E. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. Brain 1992; 115: 17831806.
  • 32
    Nelson HE. Modified card sorting test sensitive to frontal lobe defects. Cortex 1976; 12: 313324.
  • 33
    Reitan RM. Validity of the Trail Making Test as an indication of organic brain damage. Percepual and Motor Skills 1958; 8: 271276.
  • 34
    Stroop JR. Studies of interference in serial verbal reactions. Journal of Experimental Psychology 1935; 18: 643662.
  • 35
    Benton AL. Differential bahavioral effects in frontal lobe disease. Neuropsychologia 1968; 6: 5360.
  • 36
    Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV. Different effects of dopaminergic and antticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain 1992; 115: 17011725.
  • 37
    Bozeat S, Gregory CA, Ralph MA, Hodges JR. Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease? Journal of Neurology Neurosurgery Psychiatry 2000; 69: 178186.
  • 38
    McKeith IG, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurology 2005; 4: 735742.
  • 39
    Finkel S, Burns A. Introduction. In: AmesD, O'BrienJ, eds. Behavioral and Psychological Symptoms of Dementia (BPSD): A Clinical and Research Update. International Psychogeriatrics 2000; 12: (Suppl. 13): 912.
  • 40
    Neary D, Snowden JS. Clinical features of frontotemporal dementia. In: PasquierF, LebertF, ScheltensPh, eds. Frontotemporal Dementia Current Issues in Neurodegeneration, Vol. 8. Dordrecht: ICG Publications, 1996: 3147.
  • 41
    Hwang TJ, Cummings JL. Neuropsychiatric symptoms of mild cognitive impairment. In: GauthierS, ScheltensPh, CummingsJL, eds. Alzheimer's Disease and Related Disorders Annual 2004. London: Martin Dunitz, 2004: 7180.
  • 42
    Gustavson AR, Cummings JL. Assessment and Treatment of Neuropsychiatric Symptoms in Alzheimer's disease. In: RichterRW, RichterZR, eds. Alzheimer's Disease. A Physician's Guide to Practical Management. Totowa, NJ: Humana Press, 2004: 371385.
  • 43
    Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 23082314.
  • 44
    Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. Journal of Clinical Psychiatry 1987; 48(Suppl. 9): 915.
  • 45
    Allen NH, Gordon S, Hope T, Burns A. Manchester and Oxford Universities Scale for the Psychopathological Assessment of Dementia (MOUSEPAD). British Journal of Psychiatry 1996; 169: 293307.
  • 46
    Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46: 130135.
  • 47
    Boeve B, Silber M, Ferman T, et al. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Movement Disorders 2001; 16: 622630.
  • 48
    Galasko D, Bennett D, Sano M, et al. and the Alzheimer's Disease Cooperative Study. An Inventory to assess activities of daily living for clinical trials in Alzheimer‘s disease. Alzheimer‘s Disease and Associated Disorders 1997; 11(Suppl.2): S33S39.
  • 49
    Pfeffer RI, Kurosaki TT, Harrah CH, et al. Measurement of functional activities in older adults in the community. Journal of Gerontology 1982; 37: 323329.
  • 50
    DeJong R, Osterlund OW, Roy GW. Measurement of quality of life changes in patients with Alzheimer's disease. Clinical Therapy 1989; 11: 545554.
  • 51
    Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia. American Journal of Occupational Therapy 1999; 53: 471481.
  • 52
    Doraiswamy M, Leon J, Cummings JL, Martin D, Neumann PJ. Prevalence and impact of medical comorbidity in Alzheimer's disease. The journals of gerontology Series A, Biological Sciences and Medical Sciences 2002; 57: 7377.
  • 53
    Fu C, Chute DJ, Farag ES, Garakian J, Cummings JL, Vinters HV. Comorbidity in dementia: an autopsy study. Archives of Pathology and Laboratory Medicine 2004; 128: 3238.
  • 54
    Ott A, Breteler MM, Van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. British Medical Journal 1995; 310: 970973.
  • 55
    Clarfield AM. The decreasing prevalence of reversible dementias: an updated meta-analysis. Archives of Internal Medicine 2003; 163: 22192229.
  • 56
    Hejl AM, Høgh P, Waldemar G. Potentially reversible conditions in 1000 consecutive memory clinic patients. Journal of Neurology, Neurosurgery, and Psychiatry 2002; 73: 390394.
  • 57
    Farina E, Pomati S, Mariani C. Observations on dementias with possibly reversible symptoms. Aging 1999; 11: 323328.
  • 58
    Foster GR, Scott DA, Payne S. The use of CT scanning in dementia. A systematic review. International Journal of Technology Assessments in Health Care 1999; 15: 40623.
  • 59
    Condefer KA, Haworth J, Wilcock GK. Clinical utility of computed tomography in the assessment of dementia: e memory clinic study. International Journal of Geriatric Psychiatry 2004; 19: 414421.
  • 60
    Gifford DR, Holloway RG, Vickrey BG. Systematic review of clinical prediction rules for neuroimaging in the evaluation of dementia. Archives of Internal Medicine 2000; 160: 28552862.
  • 61
    DeCarli C, Murphy DG, McIntosh AR, Teichberg D, Schapiro MB, Horwitz B. Discriminant analysis of MRI measures as a method to determine the presence of dementia of the Alzheimer type. Psychiatry Research 1995; 57: 119130.
  • 62
    Jack CR Jr, Petersen RC, O'Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 1992; 42: 183188.
  • 63
    Killiany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Archives of Neurology 1993; 50: 949954.
  • 64
    De Leon MJ, George AE, Stylopoulos LA, Smith G, Miller DC. Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet 1989; 2: 672673.
  • 65
    De Leon MJ, Convit A, DeSanti S, et al. Contribution of structural neuroimaging to the early diagnosis of Alzheimer's disease. International Psychogeriatrics 1997; 9(Suppl. 1): 183190.
  • 66
    Frisoni GB, Geroldi C, Beltramello A, et al. Radial width of the temporal horn: a sensitive measure in Alzheimer disease. American Journal of Neuroradiology 2002; 23: 3547.
  • 67
    Scheltens P, Launer LJ, Barkhof F, Weinstein HC, Jonker C. The diagnostic value of magnetic resonance imaging and technetium 99 m-HMPAO single-photon-emission computed tomography for the diagnosis of Alzheimer disease in a community-dwelling elderly population. Alzheimers Disease and Associeated Disorders 1997; 11: 6370.
  • 68
    Scheltens P, Launer LJ, Barkhof F, Weinstein HC, Van Gool WA. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. Journal of Neurology 1995; 242: 557560.
  • 69
    Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in ‘probable’ Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. Journal of Neurology, Neurosurgery, and Psychiatry 1992; 55: 967972.
  • 70
    De Leon MJ, Convit A, George AE, et al. In vivo structural studies of the hippocampus in normal aging and in incipient Alzheimer's disease. Annals of the New York Academy of Sciences 1996; 777: 113.
  • 71
    O'Brien JT, Ames D, Schweitzer I, Chiu E, Tress B. Temporal lobe magnetic resonance imaging can differentiate Alzheimer's disease from normal ageing, depression, vascular dementia and other causes of cognitive impairment. Psychological Medicine 1997; 27: 12671275.
  • 72
    Desmond PM, O'Brien JT, Tress BM, et al. Volumetric and visual assessment of the mesial temporal structures in Alzheimer's disease. Australian and New Zealand Journal of Medicine 1994; 24: 547553.
  • 73
    Wahlund LO, Julin P, Johansson SE, Scheltens P. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. Journal of Neurology, Neurosurgery, and Psychiatry 2000; 69: 630635.
  • 74
    Erkinjuntti T, Lee DH, Gao F, et al. Temporal lobe atrophy on magnetic resonance imaging in the diagnosis of early Alzheimer's disease. Archives of Neurology 1993; 50: 305310.
  • 75
    Frisoni GB, Weiss C, Geroldi C, Bianchetti A, Trabucchi M. Linear measures of atrophy in mild Alzheimer's disease. American Journal of Neuroradiology 1996; 17: 913923.
  • 76
    Pucci EBN, Regnicolo L, Nolfe G, Signorino M, Salvolini U, Angeleri F. Hippocampus and parahippocampal gyrus linear measurements based on magnetic resonance in Alzheimer's disease. European Journal of Neurology 1998; 39: 1625.
  • 77
    Wahlund LO, Julin P, Lindqvist J, Scheltens P. Visual assessment of medical temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry. Psychiatry Research 1999; 90: 193199.
  • 78
    Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurology 2002; 1: 1321.
  • 79
    Chetelat G, Baron JC. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage 2003; 18: 525541.
  • 80
    Galton CJ, Gomez-Anson B, Antoun N, et al. Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia. Journal of Neurology, Neurosurgery, and Psychiatry 2001; 70: 165173.
  • 81
    Boccardi M, Laakso MP, Bresciani L, et al. The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia. Neurobiology of Aging 2003; 24: 95103.
  • 82
    Chan D, Fox NC, Jenkins R, Scahill RI, Crum WR, Rossor MN. Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology 2001; 57: 17561763.
  • 83
    Varma AR, Adams W, Lloyd JJ, Carson KJ, Snowden JS, Testa HJ, Jackson A, Neary D. Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer's disease, frontotemporal dementia and vascular dementia. Acta Neurologica Scandinavica 2002; 105: 261269.
  • 84
    Van Straaten EC, Scheltens P, Knol DL, Van Buchem MA, et al. Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. Stroke 2003; 34: 19071912.
  • 85
    Snowdon DAGL, Mortimer JA, Riley KP, Greiner PA, Markesberry WR. Brain infarction and the clinical expression of Alzheimer disease. Journal of the American Medical Association 1997; 277: 813817.
  • 86
    Schroter AZI, Henkel K, Tschampa HJ, Finkenstaedt M, Poser S. Magnetic Resonance Imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. Archives of Neurology 2000; 57: 17511757.
  • 87
    Collie DASR, Zeidler M, Colchester AC, Knight R, Will RG. MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. Clinical Radiology 2001; 56: 726739.
  • 88
    Kitagaki H, Hirono N, Ishii K, Mori E. Corticobasal degeneration: evaluation of cortical atrophy by means of hemispheric surface display generated with MR images. Radiology 2000; 216: 3138.
  • 89
    Vanneste JA. Diagnosis and management of normal-pressure hydrocephalus. Journal of Neurology 2000; 247: 514.
  • 90
    Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 1999; 52: 11531158.
  • 91
    Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. American Journal of Geriatric Psychiatry 2004; 12: 554570.
  • 92
    Patwardhan MB, McCrory DC, Marchar DB, Sams GP, Rutschmann OT. Alzheimer disease: operating characteristics of PET: a meta-analysis. Radiology 2004; 231: 7380.
  • 93
    Jagust W, Chui H, Lee A-Y. Functional imaging in dementia. In: QuizilbashN, SchneiderLS, ChuiH, TariotP, et al. (eds). Evidence-Based Dementia Practice. Oxford, UK: Blackwell, 2002: 162169.
  • 94
    Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. Journal of the American Medical Association 2001; 286: 21202127.
  • 95
    O'Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Archives of Neurology 2004; 61: 919925.
  • 96
    Walker Z, Costa DC, Walker RWH, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. Journal of Neurology, Neurosurgery, and Psychiatry 2002; 73: 134140.
  • 97
    Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurology 2006; 5: 7586.
  • 98
    McKeith IG, Dickson D, Emre M, et al. Dementia with lewy bodies: diagnosis and management: third report of the DLB consortium. Neurology 2005; 65: 18631872.
  • 99
    Chan D, Walters RJ, Sampson EL, Schott JM, Smith SJ, Rossor MN. EEG abnormalities in frontotemporal lobar degeneration. Neurology 2004; 62: 16281630.
  • 100
    Jelic V, Wahlund L-O, Almkvist O, et al. Diagnostic accuracies of quantitative EEG and PET in mild Alzheimer's disease. Alzheimer's Reports 1999; 2: 291298.
  • 101
    Jelic V, Johansson S-E, Almkvist O, et al. Quantitative EEG in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer's disease. Neurobiolology of Aging 2000; 21: 533540.
  • 102
    Claus JJ, Kwa VIH, Teunisse S, et al. Slowing on quantitative spectral EEG is a marker for rate of subsequent cognitive and functional decline in early Alzheimer disease. Alzheimer's Disease and Associated Disorders 1998; 12: 167174.
  • 103
    Claus JJ, Strijers RL, Jonkman EJ, et al. The diagnostic value of electroencephalography in mild senile Alzheimer's Disease. Clinical Neurophysiology 1999; 110: 825832.
  • 104
    Robinson DJ, Merskey H, Blume WT, Fry R, Williamson PC, Hachinski VC. Electro-encephalography as an aid in the exclusion of Alzheimer's disease. Archives of Neurology 1994; 51: 280284.
  • 105
    Zerr I, Pocchiari M, Collins S, et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000; 55: 811815.
  • 106
    Steinhoff BJ, Racker S, Herrendorf G, Poser S, Grosche S, Zerr I, Kretzschmar H, Weber T. Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Archives of Neurology 1996; 53: 162166.
  • 107
    Zeman AZ, Boniface SJ, Hodges JR. Transient epileptic amnesia: a description of the clinical and neuropsychological features in 10 cases and a review of the literature. Journal of Neurology, Neurosurgery, and Psychiatry 1998; 64: 435443.
  • 108
    Høgh P, Smith SJ, Scahill RI, et al. Epilepsy presenting as AD: neuroimaging, electroclinical features, and response to treatment. Neurology 2002; 58: 298301.
  • 109
    Sunderland T, Linker G, Mirza N, et al. Decreased β-Amyloid 1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. Journal of the American Medical Association 2003; 289: 20942103.
  • 110
    Blennow K, Hampel H. Cerebrospinal fluid markers for incipient Alzheimer's disease. Lancet Neurology 2003; 2: 605613.
  • 111
    Blennow K, Vanmechelen E. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Research Bulletin 2003; 61: 235242.
  • 112
    Sjögren M, Vanderstichele H, Ågren H, et al. Tau and Aβ42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clinical Chemistry 2001; 47: 17761781.
  • 113
    Verbeek MM, De Jong D, Kremer HPH. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Annals of Clinical Biochemistry 2003; 40: 2540.
  • 114
    Schoonenboom SNM, Pijnenburg YAL, Mulder C, et al. Amyloid β 1–42 and phosphorylated tau in CSF as markers for early onset Alzheimer's disease. Neurology 2004; 62: 15801584.
  • 115
    Pijnenburg YAL, Schoonenboom NSM, Rosso SM, et al. CSF tau and Aβ42 are not useful in the diagnosis of frontotemporal lobar degeneration. Neurology 2004; 62: 1649.
  • 116
    Tapiola T, Pirttila T, Mehta PD, Alafuzofff I, Lehtovirta M, Soininen H. Relationship between apoE genotype and CSF beta-amyloid (1–42) and tau in patients with probable and definite Alzheimer's disease. Neurobiology of Aging 2000; 21: 735740.
  • 117
    Clark CM, Sharon X, Chittams J, et al. Cerebrospinal fluid Tau and β-Amyloid. How well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Archives of Neurology 2003; 60: 16961702.
  • 118
    Strozyk D, Blennow K, White LR, Launer LJ. CSF Aβ42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003; 60: 652656.
  • 119
    Riemenschneider M, Wagenpfeil S, Diehl J, et al. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 2002; 58: 16221628.
  • 120
    Kanemaru K, Kameda N, Yamanouchi H. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 2000; 54: 18751876.
  • 121
    Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using beta amyloid 1–42 and tau levels in CSF. Neurology 1999; 52: 15551562.
  • 122
    Nagga K, Gottfries J, Blennow K, Marcusson J. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1–42) in the differentiation between Alzheimer's disease and vascular dementia. Dementia Geriatric Cognitive Disorders 2002; 14: 183190.
  • 123
    Van Everbroeck B, Green AJ, Pals P, Martin JJ, Cras P. Decreased levels of amyloid-beta 1–42 in cerebrospinal fluid of Creutzfeldt–Jakob disease patients. Journal of Alzheimers Disease 1999; 1: 419424.
  • 124
    Kapaki E, Paraskevas GP, Zalonis I, Zournas C. CSF tau protein and β-amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal aging and other dementias in the Greek population. European Journal of Neurology 2003; 10: 119128.
  • 125
    Green AJE, Harvey RJ, Thompson EJ, Rossor MN. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neuroscience Letters 1999; 259: 133135.
  • 126
    Fabre SF, Forsell C, Viitanen M, et al. Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon 4 frequency, but no tau gene mutations. Experimental Neurology 2001; 168: 413418.
  • 127
    Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease. Neurology 2002; 58: 192197.
  • 128
    Andreasen N, Vanmechelen E, Van de Voorde A, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. Journal of Neurology, Neurosurgery, and Psychiatry 1998; 64: 298305.
  • 129
    Blennow K, Wallin A, Ågren H, et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease? Molecular Chemistry and Neuropathology 1995; 26: 231245.
  • 130
    Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Archives of Neurology 2001; 58: 373379.
  • 131
    Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E. Highly increased CSF tau protein and decreased beta-amyloid (1–42) in sporadic CJD: a discrimation from Alzheimer's disease? Journal of Neurology, Neurosurgery, and Psychiatry 2001; 71: 401403.
  • 132
    Lemstra AW, Van Meegen MT, Vreyling JP, et al. 14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: a prospective study in 112 patients. Neurology 2000; 55: 514516.
  • 133
    Zerr I, Bodemer M, Gefeller O, et al. Detection of 14-3-3 protein in the cerebrospinal supports the diagnosis of Creutzfeldt Jakob disease. Annals of Neurology 1998; 43: 3240.
  • 134
    Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P. A prospective study of CSF markers in 250 patients with possible Creutzfeldt–Jakob disease. Journal of Neurology, Neurosurgery, and Psychiatry 2003; 74: 12101214.
  • 135
    Poser S, Mollenhauer B, Krauss A, et al. How to improve the clinical diagnosis of Creutzfeldt Jakob Disease. Brain 1999; 122: 23452351.
  • 136
    Lemstra AW, Van Meegen M, Baas F, Van Gool WA. [Clinical algorithm for cerebrospinal fluid test of 14-3-3 protein in diagnosis of Creutzfeldt-Jacob disease]. Nederlands Tijdschrift voor Geneeskunde 2001; 145: 14671471.
  • 137
    Houlden H, Baker M, Adamson J, et al. Frequency of tau mutations in three series of non-Alzheimer's degenerative dementia. Annals of Neurology 1999; 46: 243248.
  • 138
    Harper PS, Morris MJ, Tyler A. Genetic testing for Huntington's disease. British Medical Journal 1990; 300: 10891090.
  • 139
    Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centres Consortium on Apolipoprotein E and Alzheimer's Disease. New England Journal of Medicine 1998; 338: 506511.
  • 140
    Markus HS, Martin RJ, Simpson MA, et al. Diagnostic strategies in CADASIL. Neurology 2002; 59: 11341138.
  • 141
    Alzheimer Europe. Lawnet – Final report. http://www.alzheimer-europe.org 2000 (accessed February 24, 2006).
  • 142
    Alzheimer Europe. Recommendations on How to Improve the Legal Rights and Protection of Adults with Incapacity due to Dementia. http://www.alzheimer-europe.org , 2001 (accessed February 24, 2006).
  • 143
    Fearnley K, McLennan J, Weaks D. The Right to Know – Sharing the Diagnosis of Dementia. Edinburgh: Alzheimer Scotland – Action on Dementia, 1999.
  • 144
    Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. British Medical Journal 1999; 318: 633638.
  • 145
    Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia 1996; 7: 293303.
  • 146
    Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Archives of Internal Medicine 1998; 158: 10211031.
  • 147
    Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 22612268.
  • 148
    Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 22692276.
  • 149
    Brodaty H, Cory-Bloom J, Potocnik FC, Tryen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2005; 20: 120132.
  • 150
    Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. The Cochrane Database of Systematic Reviews 2006, issue 1. art no.: CD001190. DOI: 10.1002/14651858.CD001190.pub2.
  • 151
    Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. The Cochrane Database of Systematic Reviews 2000, issue 4. art no.: CD001191. DOI: 10.1002/14651858.CD001191.
  • 152
    Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. The Cochrane Database of Systematic Reviews 2006, issue 1. art no.: CD001747. DOI: 10.1002/14651858.CD001747.pub3.
  • 153
    NICE. Alzheimer's Disease – Donepezil, Rivastigmine and Galantamine. London, UK: NICE Tehnology Appraisal Guidance-No 19.2001 http://www.nice.org.uk (accessed February 24, 2006).
  • 154
    Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489495.
  • 155
    Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481488.
  • 156
    AD 2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD 2000): randomized double-blind trial. The Lancet 2004; 363: 21052115.
  • 157
    Pirttala T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. European Journal of Neurology 2004; 11: 734741.
  • 158
    Rogers S, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. European Neuropsychopharmacology 2000; 10: 195203.
  • 159
    Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, Wetterholm A-L, Haglund A, Zhang R, Schindler R and the Donepezil Nordic Study Group. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Impairment 2006; 21: 353363.
  • 160
    Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E, Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613620.
  • 161
    Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. Journal of the American Medical Association 2003; 289: 210216.
  • 162
    Seltzer B, Zolnouni B, Nunez M, et al. Donepezil ‘402’ study group. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Archives of Neurology 2004; 61: 18521856.
  • 163
    Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Current Medical Research Opinion 2005; 21: 13171327.
  • 164
    Auriacombe S, Pere J-J, Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezeil. Current Medical Research and Opinion 2002; 18: 129138.
  • 165
    Bartorelli L, Giraldi C, Saccardo M, et al. Effects of switching from and AChEI to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Current Medical Research and Opinion 2005; 21: 18091818.
  • 166
    Livingston G, Katona C. How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. International Jopurnal of Geriatric Psychiatry 2000; 15: 203207.
  • 167
    Clegg A, Bryant J, Nicholson T, et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technology Assessments 200; 5: 1137.
  • 168
    Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine 2003; 348: 13331341.
  • 169
    Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Journal of the American Medical Association 2004; 291: 317324.
  • 170
    Winblad B, Poritis N. Memantine in severe dementia: results of the M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). International Journal of Geriatric Psychiatry 1999; 14: 135146.
  • 171
    Areosa Sastre A, Sherriff F, McShane R. Memantine for dementia. The Cochrane Database of Systematic Reviews 2005, issue 3. art. no.: CD003154. DOI: 10.1002/14651858.CD003154.pub4.
  • 172
    Wimo A, Winblad B, Stöffler A, Wirth Y, Möbius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003; 21: 327340.
  • 173
    Kanowski S, Herrmann WM, Stephan K, Wierich W, Horr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996; 29: 4756.
  • 174
    Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. Journal of the American Medical Association 1997; 278: 13271332.
  • 175
    Van Dongen M, Van Rossum E, Kessels A, Sielhorst H, Knipschild P. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. Journal of Clinical Epidemiology 2003; 56: 367376.
  • 176
    Birks J, Grimley Evans J. Ginkgo Biloba for cognitive impairment and dementia. The Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No.: CD003120. DOI: 10.1002/14651858.CD003120.
  • 177
    Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New England Journal of Medicine 1997; 336: 12161222.
  • 178
    Tabet N, Birks J, Grimley Evans J, Orrel M, Spector A. Vitamin E for Alzheimer's disease. The Cochrane Database of Systematic Reviews 2000, issue 4. art. no.: CD002854. DOI: 10.1002/14651858.CD002854.
  • 179
    Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine 2005; 142: 3746.
  • 180
    McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47: 425432.
  • 181
    Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 16091611.
  • 182
    Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999; 53: 197201.
  • 183
    Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000; 54: 588593.
  • 184
    Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001; 358: 455460.
  • 185
    Aisen PS, Schafer KA, Grundman M et al. Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen versus placebo on Alzheimer disease progression: a randomized controlled trial. Journal of the American Medical Association 2003; 289: 28192826.
  • 186
    Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62: 6671.
  • 187
    Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 16271631.
  • 188
    Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Archives of Neurology 2000; 57: 14391443.
  • 189
    Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Archives Neurology 2002; 59: 223227.
  • 190
    Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 2004; 23: 9498.
  • 191
    Shepherd J, Blauw GJ, Murphy MB et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 16231630.
  • 192
    Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Current Alzheimer Research 2005; 2: 343353.
  • 193
    Scott HD, Laake K. Statins for the prevention of Alzheimer's disease. The Cochrane Database of Systematic Reviews 2001, issue 3. art. no.: CD003160. DOI: 10.1002/14651858. CD003160.
  • 194
    Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 2000; 54: 20612066.
  • 195
    Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000; 54: 295301.
  • 196
    Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. Journal of the American Medical Association 2000; 283: 10071015.
  • 197
    Thal LJ, Thomas RG, Mulnard R, Sano M, Grundman M, Schneider L. Estrogen levels do not correlate with improvement in cognition. Archives of Neurology 2003; 60: 209212.
  • 198
    Hogervorst E, Yaffe K, Richards M, Huppert F. Hormone replacement therapy to maintain cognitive function in women with dementia. The Cochrane Database of Systematic Reviews 2002, issue 3. art. no.: CD003799. DOI: 10.1002/14651858.CD003799.
  • 199
    Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. Journal of the American Medical Association 2003; 289: 26512662.
  • 200
    Birks J, Flicker L. Selegiline for Alzheimer's disease. The Cochrane Database of Systematic Reviews 2003, issue 1. art. no.: CD000442. DOI: 10.1002/14651858.CD000442.
  • 201
    Fioravanti M, Flicker L. Nicergoline for dementia and other age associated forms of cognitive impairment. The Cochrane Database of Systematic Reviews 2001, issue 4. art. no.: CD003159. DOI: 10.1002/14651858.CD003159.
  • 202
    López-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. The Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD000147. DOI: 10.1002/14651858.CD000147.
  • 203
    Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment. The Cochrane Database of Systematic Reviews 2004, issue 1. art. no.: CD001011. DOI: 10.1002/14651858.CD001011.
  • 204
    Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 23232330.
  • 205
    Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003; 61: 479486.
  • 206
    Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 12831290.
  • 207
    Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV, GAL-INT-6 Study Group. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clinical Therapeutics 2003; 25: 17651782.
  • 208
    Craig D, Birks J. Galantamine for vascular cognitive impairment. The Cochrane Database of Systematic Reviews 2006, issue 1. art. no.: CD004746. DOI: 10.1002/14651858.CD004746.pub2.
  • 209
    Craig D, Birks J. Rivastigmine for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2004, issue 2. art. no.: CD004744. DOI: 10.1002/14651858.CD004744.pub2.
  • 210
    Malouf R, Birks J. Donepezil for vascular cognitive impairment. The Cochrane Database of Systematic Reviews 2004, issue 1. art. no.: CD004395. DOI: 10.1002/14651858.CD004395.pub2.
  • 211
    Wilcock G, Möbius HJ, Stöffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). International Clinical Psychopharmacology 2002; 17: 297305.
  • 212
    Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33: 18341839.
  • 213
    Möbius HJ, Stöffler A. New approaches to clinical trials in vascular dementia: memantine in small vessel disease. Cerebrovascular Disease 2002; 13(Suppl. 2): 6166.
  • 214
    Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittel-Forschung 1991; 41: 773780.
  • 215
    Görtelmeyer R, Erbler H. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittel-Forschung 1992; 42: 904913.
  • 216
    Meyer JS, Chowdhury MH, Xu G, Li YS, Quach M. Donepezil treatment of vascular dementia. Annals of the New York Academy of Sciences 2002; 977: 482486.
  • 217
    Rands G, Orrel M, Spector A, Williams P. Aspirin for vascular dementia. The Cochrane Database of Systematic Reviews 2000, issue 4. art. no.: CD001296. DOI: 10.1002/14651858.CD001296.
  • 218
    Sha MC, Callahan CM. The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review. Alzheimer's Disease and Associated Disorders 2003; 17: 4654.
  • 219
    Pantoni L, Bianchi C, Beneke M, Inzitari D, Wallin A, Erkinjuntti T. The Scandinavian multi-infarct dementia trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. Journal of Neurological Science 2000; 175: 116123.
  • 220
    Pantoni L, Del Ser T, Soglian AG, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke 2005; 36: 619624.
  • 221
    Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. Journal of Geriatric Psychiatry and Neurology 2004; 17: 164171.
  • 222
    Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomized double blind placebo controlled crossover study. Journal of Neurology, Neurosurgery, and Psychiatry 2005; 76: 903904.
  • 223
    Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine 2004; 351: 25092518.
  • 224
    McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, Perry EK. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. International Journal of Geriatric Psychiatry 2000; 15: 387392.
  • 225
    Sabbagh M, Hake A, Ahmed S, Farlow M. The use of memantine in dementia with Lewy bodies. Journal of Alzheimer's Disease 2005; 7: 285289.
  • 226
    Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005; 65: 481482.
  • 227
    Fabbrini G, Barbanti P, Bonifati V, et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurologica Scandinavica 2001; 103: 123125.
  • 228
    Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001; 57: 467473.
  • 229
    Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. Journal of Clinical Psychiatry 1997; 58: 212216.
  • 230
    Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. European Neurology 2003; 49: 1319.
  • 231
    Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology 2004; 172: 400408.
  • 232
    Lonergan E, Luxenberg J, Colford J, Birks J. Haloperidol for agitation in dementia. The Cochrane Database of Systematic Reviews 2002, issue 2. art. no.: CD002852. DOI: 10.1002/14651858.CD002852.
  • 233
    O'Brien JT, Ballard CG. Treating behavioural and psychological signs in Alzheimer's disease (editorial). British Medical Journal 1999; 319: 138139.
  • 234
    Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. The Cochrane Database of Systematic Reviews 2006, issue 1. art. no.: CD003476. DOI: 10.1002/14651858.CD003476.pub2.
  • 235
    UK Committee on Safety of Medicines New advice issued on risperidone and olanapine, 2004. http://www.mhra.gov.uk (accessed February 24, 2006).
  • 236
    Carson S, McDonagh MS, Peterson K, et al. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. Journal of the American Geriatric Association 2006; 54: 354361.
  • 237
    Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association 2005; 294: 19341943.
  • 238
    Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional versus atypical antipsychotic medications. New England Journal of Medicine 2005; 353: 23352341.
  • 239
    McKeith IG, Fairbairn AF, Perry RH, Thompson P, Perry EK. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. British Medical Journal 1992; 305: 673678.
  • 240
    Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. American Journal of Geriatric Psychiatry 2001; 9: 400405.
  • 241
    Lonergan ET, Luxenberg J. Valproate preparations for agitation in dementia. The Cochrane Database of Systematic Reviews 2004, issue 2. art. no.: CD003945. DOI: 10.1002/14651858.CD003945.pub2.
  • 242
    Bains J, Birks JS, Dening TD. Antidepressants for treating depression in dementia. The Cochrane Database of Systematic Reviews 2002, issue 4. art. no.: CD003944. DOI: 10.1002/14651858.CD003944.
  • 243
    Brodaty H, Green A, Koschera A. Meta-analysis of psychosocial interventions for caregivers of people with dementia. Journal of the American Geriatric Society 2003; 51: 657664.
  • 244
    Sörensen S, Pinquart M, Habil ??, Duberstein P. How effective are interventions with caregivers? An updated meta-analysis. The Gerontologist 2002; 42: 356372.
  • 245
    Pusey H, Richards R. A systematic review of the effectiveness of psychosocial interventions for carers of people with dementia. Aging and Mental Health 2001; 5: 107119.
  • 246
    Mittelmann MS, Ferris SH, Shulman E, Steinberg G, Ambinder A, Mackell JA, Cohen J. A comprenhesive support program: effect on depression in spouse-caregivers of AD patients. The Gerontologist 1995; 35: 792803.
  • 247
    Mittelmann MS, Ferris SH, Steinberg G, et al. An intervention that delays institutionalization of Alzheimer's disease patients: treatment of spouse-caregivers. The Gerontologist 1993; 33: 730740.
  • 248
    Thompson CA, Spilsbury K, Barnes C. Information and support interventions for carers of people with dementia. (Protocol) The Cochrane Database of Systematic Reviews 2003, issue 4. art. no.: CD004513. DOI: 10.1002/14651858.CD004513.
  • 249
    British Medical Association. Assessment of Mental Capacity: Guidance for Doctors and Lawyers. A Report of the British Medical Association and The Law Society. Plymouth: Latimer Trend and Company Ltd, 1995.
  • 250
    Johannson K, Lundberg C. The 1994 International Consensus Conference on Dementia and Driving: a brief report. Swedish National Road Administration. Alzheimer's Disease and Associated Disorders 1997; 11(Suppl. 1): 6269.
  • 251
    Hunt LA, Murphy CF, Carr D, Duchek JM, Buckles V, Morris JC. Reliability of the Washington University Road Test: a performance-based assessment for drivers with dementia of the Alzheimer type. Archives of Neurology 1997; 54: 707712.
  • 252
    Dubinsky RM, Stein AC, Lyons K. Practice parameter: risk of driving and Alzheimer's disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54: 22052211.
  • 253
    White S, O'Neill D. Health and relicensing policies for older drivers in the European Union. Gerontology 2000; 46: 146152.